What is the official website of Proxycare Pharmacy ?

The official website of Proxycare Pharmacy is http://proxycarerx.com.

What is Proxycare Pharmacy's cybersecurity risk score?

Proxycare Pharmacy has an AI-generated cybersecurity risk score of 696 out of 1000, indicating a Weak security posture according to Rankiteo's assessment.

How many security incidents has Proxycare Pharmacy experienced?

According to Rankiteo, Proxycare Pharmacy currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Proxycare Pharmacy been affected by any supply chain cyber incidents ?

According to Rankiteo, Proxycare Pharmacy has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Proxycare Pharmacy have SOC 2 Type 1 certification ?

According to Rankiteo, Proxycare Pharmacy is not certified under SOC 2 Type 1.

Does Proxycare Pharmacy have SOC 2 Type 2 certification ?

According to Rankiteo, Proxycare Pharmacy does not hold a SOC 2 Type 2 certification.

Does Proxycare Pharmacy comply with GDPR ?

According to Rankiteo, Proxycare Pharmacy is not listed as GDPR compliant.

Does Proxycare Pharmacy have PCI DSS certification ?

According to Rankiteo, Proxycare Pharmacy does not currently maintain PCI DSS compliance.

Does Proxycare Pharmacy comply with HIPAA ?

According to Rankiteo, Proxycare Pharmacy is not compliant with HIPAA regulations.

Does Proxycare Pharmacy have ISO 27001 certification ?

According to Rankiteo,Proxycare Pharmacy is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Proxycare Pharmacy operate in ?

Proxycare Pharmacy operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Proxycare Pharmacy have ?

Proxycare Pharmacy employs approximately 6 people worldwide.

Does Proxycare Pharmacy own any subsidiaries ?

Proxycare Pharmacy presently has no subsidiaries across any sectors.

How many LinkedIn followers does Proxycare Pharmacy have ?

Proxycare Pharmacy's official LinkedIn profile has approximately 18 followers.

What is the NAICS classification code for Proxycare Pharmacy ?

Proxycare Pharmacy is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Proxycare Pharmacy have a Crunchbase profile ?

No, Proxycare Pharmacy does not have a profile on Crunchbase.

Does Proxycare Pharmacy have a LinkedIn profile ?

Yes, Proxycare Pharmacy maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/proxycare-pharmacy.

How many cybersecurity incidents has Proxycare Pharmacy experienced ?

As of July 22, 2026, Rankiteo reports that Proxycare Pharmacy has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Proxycare Pharmacy have ?

Proxycare Pharmacy has an estimated 5,710 peer or competitor companies worldwide.

What types of cybersecurity incidents has Proxycare Pharmacy faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Proxycare Pharmacy

Boost Score +25 with badge (5 left)

696

/1000

Weak

721

/1000

Moderate

Proxycare Pharmacy Vendor Cyber Rating & Cyber Score

proxycarerx.com

Add Your Compliance Badge

Long Term Health Pharmacy Solitions

Proxycare Pharmacy A.I CyberSecurity Scoring

Scoring History

Proxycare Pharmacy

Proxycare Pharmacy CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Proxycare Pharmacy

Breach

8/2025

PRO1774989199

Loading…

A.I.

Proxycare Pharmacy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Proxycare Pharmacy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Proxycare Pharmacy in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Proxycare Pharmacy in 2026.

Incident Types Proxycare Pharmacy vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Proxycare Pharmacy in 2026.

Incident History - Proxycare Pharmacy (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Proxycare Pharmacy Subsidiaries

Parent Company

Proxycare Pharmacy

Pharmaceutical Manufacturing

Website: http://proxycarerx.com

Company Size: 51-200 employees

No subsidiary data available for this company.

Loading…

Proxycare Pharmacy Similar Companies

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Loading…

NEWS

Proxycare Pharmacy CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 01, 2026 01:59 PM

Proxycare Data Breach Reported; Attorneys Investigating

Was your information compromised in the Proxycare data breach? Learn more about the security incident and how a class action lawsuit may...

Read Article

March 31, 2026 08:41 PM

ProxyCare Inc Data Breach Exposes Social Security numbers

ProxyCare Inc, a pharmacy services company headquartered in Sunrise, Florida, disclosed a data breach that the company first discovered on...

Read Article

March 31, 2026 08:21 PM

Proxycare Data Breach Lawsuit Investigation

If you were affected by the Proxycare data breach, you may be entitled to compensation.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-63261

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-72/388575

CVE-2026-63260

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-71/388574

CVE-2026-63259

SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-9-4-4-security-update-esa-2026-70/388573

CVE-2026-63145

SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-69/388572

CVE-2026-63144

SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-19-9-3-8-9-4-4-security-update-esa-2026-68/388571

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…